- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01447732
Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors
Two-Part, Open-Label, Multi-Center Phase 1 Study of Monoclonal Antibody CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors
Study Overview
Status
Intervention / Treatment
Detailed Description
The study will be conducted in two parts. In Part 1, a standard 3+3 designed dose escalation phase, subjects will receive CEP-37250/KHK2804, administered iv, once every week. A treatment cycle will consists of total of four doses per cycle. Part 2 of the study will enroll subjects with either colon cancer or pancreatic cancer to receive CEP-37250/KHK2804 at a dose to be determined following completion of Part 1.
All subjects will receive study therapy until disease progression, the development of unacceptable toxicity, noncompliance or withdrawal of consent by the subject, or Investigator decision, up to a maximum of six cycles (approximately six months). After six cycles of CEP-37250/KHK2804 therapy, the subject may continue to receive CEP-37250/KHK2804 after discussion with the Sponsor and determination that the subject is experiencing a best response of at least stable disease (SD) and is not experiencing any unacceptable toxicities or dose limiting toxicities (DLTs).
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adequate hepatic, renal, and hematologic function;
- Life expectancy > 3 months;
- Part 1 and 2: The subject has histopathologically or cytologically documented, measurable, unresectable, locally advanced primary or recurrent, metastatic solid tumor, locally advanced primary or recurrent, metastatic pancreatic adenocarcinoma and must have received at least one prior treatment regimen containing gemcitabine or 5-FU, and locally advanced primary or recurrent, metastatic colon adenocarcinoma.
Exclusion Criteria:
Parts 1 and 2:
- Malignant melanoma, Merkel cell cancer, small cell lung cancer, lymphoepithelial carcinoma, malignant mesothelioma, GIST, Hodgkin and NHL, thymoma, neuroendocrine, neuronal tumors, and sarcomas. This list of excluded tumors may be modified as additional research findings become available on target antigen expression;
- The subject has received anti-cancer chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or investigational agents within 4 weeks (6 weeks for mitomycin C and nitrosoureas) prior to the first dose of CEP-37250/KHK2804;
- The subject has received monoclonal antibodies of any type or for any form of disease within 4 weeks of the first dose of CEP-37250/KHK2804;
- Major surgery within 4 weeks prior to the first dose;
- Known symptomatic brain metastases (screening magnetic resonance imaging (MRI) of the brain is only required when there is clinical suspicion of central nervous system [CNS] involvement or past history of treated brain metastasis). Subjects with treated brain metastasis (radiotherapy and/or surgery) will be eligible if they:
- Have completed treatment for their brain metastasis > 4 weeks prior to scheduled study treatment start date;
- Are neurologically stable;
- Are on corticosteroids in doses no greater than physiological replacement (e.g., dexamethasone < 1.5 mg/day); and
- Have a screening MRI scan of the brain that specifically verifies no evidence of CNS hemorrhage and no active gadolinium enhancing lesions;
Subjects with primary brain/CNS malignancy (e.g., gliomas, lymphomas) are excluded.
- Hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins, or allergy to any component of the CEP-37250/KHK2804 finished drug and the reaction could not be controlled or prevented on subsequent infusion with standard therapies such as antihistamines, 5-HT3 antagonists, or corticosteroids.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1
Dose escalation in subjects with advanced solid tumors with Part 1 which includes intervention of CEP-37250/KHK2804
|
Part 1 is based on the CEP-37250/KHK2804 tolerability and safety data from three subjects enrolled in a cohort, enrollment at the next dose level or additional subjects into the ongoing cohort will occur based upon the number subjects with DLT at a given dose level. Dose depends on subject's body weight. Part 1 includes intervention of CEP-37250/KHK2804. Part 2 will receive CEP-37250/KHK2804 at a dose to be determined following completion of Part 1.
Other Names:
|
Experimental: Part 2
Subjects with colorectal or pancreatic cancer Part 2 which includes intervention of CEP-37250/KHK2804
|
Part 1 is based on the CEP-37250/KHK2804 tolerability and safety data from three subjects enrolled in a cohort, enrollment at the next dose level or additional subjects into the ongoing cohort will occur based upon the number subjects with DLT at a given dose level. Dose depends on subject's body weight. Part 1 includes intervention of CEP-37250/KHK2804. Part 2 will receive CEP-37250/KHK2804 at a dose to be determined following completion of Part 1.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Event collection and assessment will be done for all 74 potentially treated subjects.
Time Frame: at least 30 days or up to 12 weeks
|
The safety of CEP-37250/KHK2804 will be determined by reported adverse events (AEs), changes in the physical examinations, vital laboratory evaluations, and treatment discontinuations due to toxicity.
|
at least 30 days or up to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess PK parameters which include: area under the plasma concentration versus time curve (AUC), peak plasma concentration (Cmax), t 1/2 and CL of CEP-37250/KHK2804.
Time Frame: at least 30 days or up to 12 weeks
|
Participating subjects will have serial blood samples taken to determine the PK profile of study drug.
|
at least 30 days or up to 12 weeks
|
To screen for the development of antibodies against CEP-37250/KHK2804 (immunogenicity)
Time Frame: at least 30 days or up to 12 weeks
|
Subjects will have serial blood samples to check for the developments of anti-CEP-37250/KHK2804 antibodies.
|
at least 30 days or up to 12 weeks
|
To evaluate preliminary efficacy (overall response (Objective response rate(ORR; Complete Response(CR)+Partial Response(PR) and clinical benefit rate(CR+PR+stable disease(SD)).
Time Frame: up to 30 days or up to 12 weeks
|
Tumor measurements and disease response assessments will be performed on all participating subjects.
|
up to 30 days or up to 12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Michael Tirgan, MD, Kyowa Hakko Kirin Pharma, Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CEP-37250/KHK2804-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adenocarcinoma of the Pancreas
-
Centre Leon BerardMerck Sharp & Dohme LLC; Debiopharm International SACompletedAdenocarcinoma of the Pancreas | Adenocarcinoma of the Rectum | Adenocarcinoma of the ColonFrance
-
Samyang Biopharmaceuticals CorporationUnknownMetastatic Adenocarcinoma of the Pancreas | Recurrent Adenocarcinoma of the PancreasKorea, Republic of
-
University of Michigan Rogel Cancer CenterCompletedAdenocarcinoma of the PancreasUnited States
-
National Cancer Institute, NaplesRecruitingAdenocarcinoma of the PancreasItaly, Spain
-
West Virginia UniversityRecruitingAdenocarcinoma of the PancreasUnited States
-
Baptist Health South FloridaAstraZenecaTerminatedAdenocarcinoma of the PancreasUnited States
-
Institut de Recherches Internationales ServierNot yet recruitingMetastatic Adenocarcinoma of the PancreasJapan
-
National Taiwan University HospitalRecruitingDuctal Adenocarcinoma of the PancreasTaiwan
-
Eastern Regional Medical CenterTerminatedMetastatic Adenocarcinoma of the PancreasUnited States
-
University Hospital, LilleMinistry of Health, FranceRecruitingAdenocarcinoma of the Pancreas | Ampullary Adenocarcinoma | Adenocarcinoma of the DuodenumFrance
Clinical Trials on CEP-37250/KHK2804
-
CephalonCompleted
-
CephalonCompletedPsoriasisUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed
-
CephalonH. Lundbeck A/S; The Parkinson Study GroupTerminatedParkinson DiseaseUnited States, Canada, Puerto Rico
-
University of Michigan Rogel Cancer CenterRecruitingPancreatic Adenocarcinoma | Pancreatic Neuroendocrine Tumor | Pancreatic Neuroendocrine Carcinoma | Adenosquamous Carcinoma | Gastrointestinal Neuroendocrine Tumor | Gastrointestinal Neuroendocrine Carcinoma | Neuroendocrine Prostate CarcinomaUnited States
-
New Approaches to Neuroblastoma Therapy ConsortiumNational Cancer Institute (NCI)CompletedNeuroblastomaUnited States, Canada
-
Edwards LifesciencesCompletedCoronary Artery Disease | Heart Failure | Aortic Valve Stenosis | Aortic Valve Insufficiency | Aortic Valve DisorderCanada, United States, Austria, Germany, Spain, United Kingdom
-
Cephalon, Inc.CompletedSystemic Lupus ErythematosusUnited States, Belgium, Czechia, France, Germany, Hungary, Poland, Portugal, Spain, Ukraine, United Kingdom
-
Cephalon, Inc.TerminatedSystemic Lupus ErythematosusUnited States, Belgium, Czechia, France, Germany, Hungary, Poland, Portugal, Spain, Ukraine, United Kingdom